Literature DB >> 2354450

Cachectic effects of recombinant human tumor necrosis factor in rats.

G Darling1, D L Fraker, J C Jensen, C M Gorschboth, J A Norton.   

Abstract

Treatment of rats with either intermittent bolus i.v. injections or continuous i.v. infusions of the same sublethal daily dose of tumor necrosis factor (TNF) results in decreased food intake and decreased nitrogen balance compared to saline-treated control rats. After 4 days of treatment, rats treated with intermittent bolus doses of TNF develop tolerance to the nutritional effects and consume normal amounts of food and have nitrogen balance similar to those of saline treated rats. Rats receiving the continuous infusion of TNF do not. Rats treated with both routes of TNF lose more weight than pair fed rats who eat the same mean amount as the continuous TNF treated group. In addition, 56% of rats receiving continuous infusion TNF die during the 8-day experimental period while rats receiving either intermittent bolus TNF or similar food intake (pair fed) do not. Body composition studies of rats that completed the 8 days of treatment indicate that rats receiving either continuous infusion or intermittent bolus TNF have increased percentages of body water and reduced percentages of body solid compared to saline treated control rats. Rats pair fed to the food intake of continuous TNF treated rats also had increased percentages of body water and reduced percentages of body solid, but changes were significantly less than those observed in continuous TNF infused rats. Continuous TNF infusion reduced total body nitrogen and potassium while pair feeding did not reduce potassium and reduced nitrogen to a lesser degree. Pair feeding and continuous TNF infusion reduced total body fat to a similar extent. Twice a day administration of TNF resulted in lesser changes in carcass water, solid, nitrogen, lipid, and potassium than continuous infusion of the same dose of TNF. The results indicate that continuous infusion of TNF can produce anorexia, weight loss, edema, loss of body protein, lipid and cell mass, and lethality which is markedly ameliorated with bolus doses of TNF. The findings are consistent with the hypothesis that slow continuous secretion of sublethal amounts of TNF may mediate cancer cachexia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354450

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Cachexia and tumour necrosis factor-alpha in cytomegalovirus infection.

Authors:  H Tilg; W Vogel; M Herold; W E Aulitzky; C Huber
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

2.  Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia.

Authors:  K G Billingsley; D L Fraker; G Strassmann; C Loeser; H M Fliot; H R Alexander
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

Review 3.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice.

Authors:  J B Roths; C L Sidman
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

5.  Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model.

Authors:  P Costelli; N Carbó; L Tessitore; G J Bagby; F J Lopez-Soriano; J M Argilés; F M Baccino
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

6.  Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression.

Authors:  M S Naylor; G W Stamp; W D Foulkes; D Eccles; F R Balkwill
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

7.  The possible role of TNF-alpha and IL-2 in inducing tumor-associated metabolic alterations.

Authors:  Y Noguchi; T Makino; T Yoshikawa; K Nomura; K Fukuzawa; A Matsumoto; T Yamada
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

8.  Epithelial ovarian cancer: a cytokine propelled disease?

Authors:  S Malik; F Balkwill
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

9.  Distribution of Photofrin between tumour cells and tumour associated macrophages.

Authors:  M Korbelik; G Krosl; P L Olive; D J Chaplin
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

10.  Humoral mediation for cachexia in tumour-bearing rats.

Authors:  L Tessitore; P Costelli; F M Baccino
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.